| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Maria Domenica Cappellini | Q56678936 |
| Irene Motta | Q64171712 | ||
| P2860 | cites work | Thalassaemia | Q39708856 |
| Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia | Q40915310 | ||
| Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers | Q40953481 | ||
| Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone. | Q42361922 | ||
| Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia | Q42361973 | ||
| Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis | Q42456197 | ||
| Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. | Q43208938 | ||
| Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women | Q44911435 | ||
| Transplantation in thalassemia: Revisiting the Pesaro risk factors 25 years later. | Q45941460 | ||
| Transferrin therapy ameliorates disease in beta-thalassemic mice. | Q50586962 | ||
| Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes | Q73416479 | ||
| Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells | Q89047120 | ||
| Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin | Q24293797 | ||
| The inherited diseases of hemoglobin are an emerging global health burden | Q27686848 | ||
| β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies | Q28086960 | ||
| Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study | Q33442629 | ||
| Reactivation of developmentally silenced globin genes by forced chromatin looping. | Q34052021 | ||
| Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. | Q34205528 | ||
| Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin | Q35828757 | ||
| miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction | Q36757075 | ||
| Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice | Q36897141 | ||
| Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera | Q37097115 | ||
| Functional footprinting of regulatory DNA. | Q37738675 | ||
| Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. | Q38073700 | ||
| HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers | Q38592271 | ||
| The mutual control of iron and erythropoiesis. | Q38830409 | ||
| Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease. | Q38904398 | ||
| 2017 Clinical trials update in new treatments of β-thalassemia | Q38922283 | ||
| Transplantation for thalassemia major: alternative donors | Q38930821 | ||
| Therapeutic potential of hepcidin - the master regulator of iron metabolism | Q39014779 | ||
| Gene Therapy for β-Hemoglobinopathies | Q39220089 | ||
| Investigational drugs in phase I and phase II clinical trials for thalassemia. | Q39328286 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 278-283 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | New therapeutic targets in transfusion-dependent and -independent thalassemia | |
| P478 | volume | 2017 |
| Q99402725 | A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand |
| Q92424160 | Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia |
| Q58580509 | Gastrointestinal iron excretion and reversal of iron excess in a mouse model of inherited iron excess |
| Q64982592 | Thyroid Disorders in Homozygous β-Thalassemia: Current Knowledge, Emerging Issues and Open Problems. |
| Q60949866 | Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model |
Search more.